The seminar covered a number of important topics, including "A Brief Overview of the Clinical Development of Endoscopy in China," "Applications of Generative AI in Oncology and Minimally Invasive Surgery," "Discussion on the Application of Artificial Intelligence in the Medical Field," "Biodesign and Innovative Design of Intelligent Medical Devices," "The Direction of AI-Enabled Minimally Invasive Instruments," and "Exploration of Minimally Invasive Surgery under AI Technology." At the meeting, Liu Lei, Managing Director of KEENSEA Medical Technology, introduced the company's products and services, business development, and other basic information to top industry experts. Participants at the seminar jointly explored KEENSEA Medical's latest research achievements in the field of minimally invasive AI and its future development path.
With the continuous development and innovation of technology,AI technology will become a vital support in the field of minimally invasive diagnosis and treatment,providing more efficient,precise,and safe medical services for both doctors and patients.According to SmartKarma,KEENSEA Medical has over 60 patents,more than 20 trademarks,and more than 30 ongoing research projects in terms of technological reserves.Among these,KEENSEA Medical's pioneering AI intelligent ultra-high-definition endoscope camera system integrates AI,the Internet,and new technologies into minimally invasive medical techniques,significantly enhancing the efficiency of endoscopes and making the products smarter and minimally invasive surgeries more precise.Amid the rapid development of AI,KEENSEA Medical is also actively promoting its R&D technology towards"Minimally Invasive 5.0."In the future,the company will focus on AI,molecular probes,multi-spectrum,intelligent navigation,AR enhancement,and infrared technologies,actively driving the intelligence and precision of its products.
